Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
- Market Cap ₹ 7.47 Cr.
- Current Price ₹ 5.53
- High / Low ₹ 6.30 / 3.20
- Stock P/E
- Book Value ₹ 0.99
- Dividend Yield 0.00 %
- ROCE -12.6 %
- ROE -12.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.58 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -3.46% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.03 | 0.04 | 0.05 | 0.10 | 0.09 | 0.05 | 0.08 | 0.08 | 0.13 | 0.11 | 0.00 | 0.00 | |
0.04 | 0.05 | 0.04 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | 0.07 | 0.09 | 0.14 | 0.23 | |
Operating Profit | -0.01 | -0.01 | 0.01 | 0.04 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | -0.14 | -0.23 |
OPM % | -33.33% | -25.00% | 20.00% | 40.00% | 33.33% | -40.00% | 0.00% | -12.50% | 46.15% | 18.18% | ||
0.02 | 0.01 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.09 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Profit before tax | 0.01 | 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.18 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
0.01 | 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.18 | |
EPS in Rs | 0.01 | 0.00 | 0.01 | 0.07 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.01 | 0.07 | -0.13 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -325% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 62% |
3 Years: | 23% |
1 Year: | 36% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | -3% |
Last Year: | -13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 13.44 | 13.44 |
Reserves | -12.20 | -12.20 | -12.19 | -12.11 | -12.08 | -12.10 | -12.09 | -12.10 | -12.05 | -12.03 | -11.92 | -12.10 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.13 | 0.13 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | |
Total Liabilities | 0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 |
0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.30 | 1.35 | |
Total Assets | 0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.00 | 0.01 | -0.05 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | 0.11 | -0.13 | |
0.02 | -0.02 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.32 | 0.17 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49 | -0.02 | |
Net Cash Flow | 0.03 | -0.02 | 0.01 | -0.02 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | -0.06 | 0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
Working Capital Days | -1,581.67 | -1,186.25 | -876.00 | 36.50 | 81.11 | 73.00 | 45.62 | 0.00 | 0.00 | 0.00 | ||
ROCE % | 120.00% | -66.67% | 0.00% | -40.00% | 133.33% | 25.00% | 9.94% |
Documents
Announcements
- Revised Audited Standalone Financial Statements Of The Company For The Year Ended March 31,2024. 1d
- Closure of Trading Window 27 Jun
- Revised Audited Standalone Financial Results For The Quarter And Financial Year Ended 31St March, 2024 25 Jun
- Revised Audited Standalone Financial Results For The Quarter And Financial Year Ended 31St March, 2024 21 Jun
- Clarification Regarding Non Disclosure Of Reasons For Delay In Submission Of Financial Results For The Period/Year Ended March 31, 2024 18 Jun
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.